#KCRS20 Presentations

Thursday Topics: Keynote, Sessions 1 & 2, Discussion

Welcome and Introductions


Bryan Lewis, KidneyCAN President
Toni Choueiri, KCRS Co-Chair, Dana-Farber Cancer Institute
Hans Hammers, KCRS Co-Chair, University of Texas Southwestern

Keynote Presentation: “Can Studies of the VHL Gene Get Us to Curative Combination Therapies for Kidney Cancer?”


Dr. William Kaelin, Jr., Nobel Laureate
Harvard/Dana-Farber Cancer Institute

The Next Frontier: New Molecular Targets for Kidney Cancer

Moderated by Eric Jonasch, MD Anderson Cancer Center, and Naomi Haas, University of Pennsylvania.

“Mammalian Stringent Response Triggered by MESH1 Inhibition”
Jen Tsan Chi, Duke University

“TBK1 Serves as a Novel Therapeutic Target in Kidney Cancers with VHL Loss” 
Qing Zhang, University of Texas Southwestern

“Targeting IGF1R Signaling in MTAP-Deficient Kidney Cancer” 
Ching-Hsien Chen, University of California Davis

“Studying BAP1 in Regulating Glucose Dependency in Renal Cancer: Mechanisms and Preclinical Translation”  
Boyi Gan, MD Anderson Cancer Center

Session One Discussion

Getting the Right Therapies to the Right Patients: Emerging Biomarkers for Kidney Cancer

Moderated by Sabina Signoretti, Dana Farber Cancer Institute, and Payal Kapur, University of Texas Southwestern.

“Characterizing and Targeting the Microenvironmental Barriers to Immunotherapeutic Response in RCC: Team Research”
Ari Hakimi & Tim Chan, Memorial Sloan Kettering Cancer Center

“Endogenous Retrovirus Expression, Chromatin Abnormalities, and Response to Immune Checkpoint Blockade in Clear Cell RCC”
Shridar Ganesan, Rutgers Cancer Institute

“Host Immune Signatures as Therapy Response Biomarkers in Metastatic Renal Cell”
Ziad Bakouny, Dana Farber Cancer Institute

“Development and Testing of Circulating-Free Methylation DNA as a Prognostic Biomarker for Recurrent Kidney Cancer”
Daniel De Carvalho, Princess Margaret Cancer Center

“Biomarkers of IO in RCC: What Is an Ideal Industry-Academic Relationship?”
Megan Wind-Rotolo, BMS Translational Medicine Team Lead

Session Two Discussion

Breakout Discussion | Variant RCC: Where Are We Now, and Where Do We Go?

Friday Topics: Sessions 3 & 4

Best of 2020: Including Updates from ESMO

Moderated by Toni Choueiri, Dana Farber Cancer Institute, and Brian Rini, Vanderbilt University.

“Translational Science Updates from ESMO”
Tom Powles, Barts Cancer Centre

“Important Clinical Updates from ESMO”
Laurence Albiges, Institut Gustave Roussy

“The Ever-Changing Clinical Landscape of Kidney Cancer Therapies: Updates and Ongoing Trials”
Robert Motzer, Memorial Sloan Kettering Cancer Center

Session Three Discussion

The Next Generation of Immune Therapies

Moderated by Hans Hammers, University of Texas Southwestern, and John Haanen, Netherlands Cancer Institute.

“Targeted Pro-Inflammatory Prodrugs for the Immunotherapy of Kidney Cancer”
Hans Hammers, University of Texas Southwestern

“Oncolytic Single-Cycle Replicating Immunotherapies for Kidney Cancer”
Michael Barry, Mayo Clinic

“Personalized T-Cell Immunotherapy for Renal Cell Carcinoma”
Shreeram Akilesh, University of Washington

“Lessons in Immunotherapy Failures”
Ira Mellman, Genentech, Cancer Immunology

Session Four Discussion

Closing & Acknowledgments


Bryan Lewis, KidneyCAN President

On-Demand Content

View pre-recorded sessions here!

The Next Frontier: New Molecular Targets for Kidney Cancer

“Profilin 1 as a Novel Target in Patients with RCC”
Partha Roy, University of Pittsburgh

Novel Models for Kidney Cancer Research

“Unlocking the Human Relevance of a New Genetic Papillary RCC Mouse Model”
Richard Link, Baylor College of Medicine

“Modeling Spatial Ecology in Clear Cell Renal Cell Carcinoma Model: A Novel Tool to Support Drug Sequencing Decisions”
Brandon Manley, H. Lee Moffitt Cancer Center

“Kidney Cancer (DFCI) Model”
Laura Stransky, Dana Farber Cancer Institute

Germline Genetics and Implications

“Biological Determinants of Kidney Cancer Health Disparities”
Khadijah Mitchell, Lafayette College

Variant Kidney Cancer Histologies: Characterization and Therapeutic Targeting

“Chromophobe RCC: New Concepts in Pathogenesis”
Elizabeth Henske, Brigham & Women’s Hospital

“Defining the Role of Beta-Catenin Activation in Wilms Tumor”
Keri Drake, University of Texas Southwestern

“Molecular Characterization and Therapeutic Targeting of TFE3 Fusion Kidney Cancers”
Srinivas Viswanathan, Dana Farber Cancer Institute